{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.40","value":"17.2"},{"groupId":"OG001","spread":"31.83","value":"26.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Time to RBC-TI was defined as the time between first dose date and the date of onset of RBC-TI first observed for participants who achieved RBC-TI of ≥ 8 weeks during Week 1 through Week 24","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All participants who achieved RBC-TI ≥ 8 weeks during Week 1 through Week 24","reportingStatus":"POSTED","timeFrame":"From first dose to Week 24 of study treatment","title":"Time to Red Blood Cell Transfusion Independence (RBC-TI) - Week 1 Through Week 24","type":"SECONDARY","unitOfMeasure":"Days"}